Novartis News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

18.02.16	Press Release: Novartis: Alcon expands leadership position in treating glaucoma through acquisition of Transcend Medical, Inc. (Dow Jones)
12.02.16	Press Release: Novartis: Sandoz strengthens its biosimilars portfolio with acquisition of Pfizer's biosimilar infliximab in EEA (Dow Jones)
11.02.16	Press Release: Novartis: Sandoz advances its biosimilars program with EMA acceptance of regulatory submission for biosimilar pegfilgrastim (Dow Jones)
27.01.16	GlobeNewswire/Novartis erzielt 2015 eine kräftige -8- (Dow Jones)
27.01.16	GlobeNewswire/Novartis erzielt 2015 eine kräftige -7- (Dow Jones)
27.01.16	GlobeNewswire/Novartis erzielt 2015 eine kräftige -6- (Dow Jones)
15.01.16	Press Release: Novartis receives two new FDA -2- (Dow Jones)
15.01.16	Press Release: Novartis receives two new FDA approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis in the US (Dow Jones)
11.01.16	Press Release: Novartis continues to grow immuno-oncology pipeline through collaboration and licensing agreement with Surface Oncology (Dow Jones)
05.01.16	Press Release: Novartis Pharmaceuticals -2- (Dow Jones)
05.01.16	Press Release: Novartis Pharmaceuticals collaborates with Qualcomm in digital innovation with the Breezhaler(TM) inhaler device to treat COPD (Dow Jones)
23.12.15	Press Release: Novartis announces NEJM -2- (Dow Jones)
23.12.15	Press Release: Novartis announces NEJM publication of two major trials showing significant efficacy of Cosentyx in ankylosing spondylitis patients (Dow Jones)
09.12.15	Press Release: 300 million child-friendly antimalarial treatments supplied without profit by Novartis (Dow Jones)
08.12.15	Press Release: Novartis: Sandoz advances its biosimilars program with European Medicines Agency (EMA) acceptance of regulatory submission for biosimilar etan... (Dow Jones)
08.12.15	Press Release: Novartis highlights new CTL019 -2- (Dow Jones)
07.12.15	Press Release: Novartis highlights new CTL019 -2- (Dow Jones)
07.12.15	Press Release: Novartis highlights new CTL019 Phase II data demonstrating 93% complete remission in pediatric patients with r/r ALL (Dow Jones)
07.12.15	Press Release: Novartis: Phase III data shows Sandoz' proposed biosimilar pegfilgrastim has similar safety and efficacy as the reference product (Dow Jones)
06.12.15	Press Release: Novartis drug PKC412 (midostaurin) -2- (Dow Jones)
06.12.15	Press Release: Novartis drug PKC412 (midostaurin) improves overall survival by 23% in global Phase III study of AML patients with FLT3 mutations (Dow Jones)
06.12.15	Press Release: Novartis announces new CTL019 -2- (Dow Jones)
06.12.15	Press Release: Novartis announces new CTL019 study data demonstrating overall response in adult patients with certain types of lymphoma (Dow Jones)
06.12.15	Press Release: Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera (Dow Jones)
05.12.15	Press Release: Novartis announces Phase III -2- (Dow Jones)
05.12.15	Press Release: Novartis announces Phase III studies of Jakavi show disease improvement in patients with myelofibrosis and polycythemia vera (Dow Jones)
02.12.15	Press Release: Novartis presents new data on -2- (Dow Jones)
02.12.15	Press Release: Novartis presents new data on targeted combination therapy at SABCS reinforcing commitment to breast cancer patients (Dow Jones)
30.11.15	Press Release: Novartis highlights clinical -2- (Dow Jones)
30.11.15	Press Release: Novartis highlights clinical advances at ASH 2015, underscoring leadership in hematology research (Dow Jones)
24.11.15	Press Release: Novartis' heart failure medicine Entresto(TM) receives EU approval (Dow Jones)
23.11.15	Press Release: Novartis receives two landmark -2- (Dow Jones)
23.11.15	Press Release: Novartis receives two landmark European approvals for Cosentyx to treat patients with ankylosing spondylitis and psoriatic arthritis (Dow Jones)
18.11.15	Press Release: Novartis: Regulatory submission for Sandoz' proposed biosimilar pegfilgrastim accepted by the FDA (Dow Jones)
17.11.15	Press Release: FLAME study shows superiority of -2- (Dow Jones)
17.11.15	Press Release: FLAME study shows superiority of Novartis' Ultibro(R) Breezhaler(R) over Seretide(R) in reducing COPD exacerbations (Dow Jones)
15.11.15	Press Release: Alcon introduces Contoura Vision -2- (Dow Jones)
15.11.15	Press Release: Alcon introduces Contoura Vision as first personalized LASIK procedure at American Academy of Ophthalmology Annual Meeting (Dow Jones)
08.11.15	Press Release: Novartis presents new two year -2- (Dow Jones)
08.11.15	Press Release: Novartis presents new two year data for Cosentyx(R) showing no progression in joint damage in 84% of psoriatic arthritis patients (Dow Jones)
08.11.15	Press Release: New two year data for Novartis' -2- (Dow Jones)
08.11.15	Press Release: New two year data for Novartis' Cosentyx(R) show sustained response and no progression in spinal damage as shown by x-ray in up to 80% of pati... (Dow Jones)
04.11.15	Press Release: Novartis nominating Elizabeth Doherty and Ton Buechner to the Board of Directors (Dow Jones)
29.10.15	Press Release: Novartis Foundation and partners -2- (Dow Jones)
29.10.15	Press Release: Novartis Foundation and partners launch new hypertension program in Ghana (Dow Jones)
28.10.15	GlobeNewswire/Novartis steigert die -4- (Dow Jones)
28.10.15	GlobeNewswire/Novartis steigert die -3- (Dow Jones)
27.10.15	GlobeNewswire/Novartis steigert die -7- (Dow Jones)
27.10.15	GlobeNewswire/Novartis steigert die -6- (Dow Jones)
23.10.15	Press Release: Novartis receives positive CHMP -2- (Dow Jones)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Sonova Hldg	295.60	0.96 %	K V
Lonza Grp	531.00	0.53 %	K V
Alcon	76.02	0.34 %	K V
Roche Hldg G	247.40	0.28 %	K V
ABB	48.86	0.27 %	K V
Swisscom	498.40	-0.62 %	K V
UBS Group	26.71	-0.67 %	K V
Zurich Insur Gr	533.00	-0.97 %	K V
Holcim	86.10	-1.01 %	K V
Sika	213.20	-2.47 %	K V

mehr

12.07.24		Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an
12.03.24		MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis
31.01.24		Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung
12.06.23		Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch
25.04.23		Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an
07.12.22		MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert
19.07.22		Novartis-Aktie höher: Novartis bei nahezu stabilen Umsätzen mit Gewinnrückgang - Umbau soll 1,5 Milliarden US-Dollar Kosten sparen
06.05.22		Novartis-Aktie im Minus: Produktion von Krebsmitteln in Italien und USA ausgesetzt

12.07.24

Novartis- und MorphoSys-Aktien gewinnen: Novartis kurbelt Squeeze-Out bei MorphoSys an

12.03.24

MorphoSys- und Novartis-Aktien uneinig: Bundeskartellamt erlaubt MorphoSys-Übernahme durch Novartis

31.01.24

Novartis-Aktie schwach: Novartis profitiert von Sandoz-Abspaltung - Gewinnsprung

12.06.23

Novartis-Aktie im Plus: Novartis legt für Chinook Milliardensumme auf den Tisch

25.04.23

Novartis-Aktie im Plus: Novartis hebt nach gutem Jahresbeginn die Umsatzprognose an

07.12.22

MorphoSys-Aktie und Novartis-Aktie gefragt: Krebsprogramm gegen Zahlung an Novartis auslizenziert